Clinical Trial Update: Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating transtympanic Lactated Ringer's solution to prevent cisplatin-induced ototoxicity (hearing loss).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss

Drugs mentioned

• Lactated Ringer's solution (Ringer's lactate solution)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Hearing Loss | Phase 1, Phase 2 | Status: UNKNOWN